Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 15, 2017 06:00 ET | Source: Mesoblast Limited

Durable Three-Year Outcomes In Degenerative Disc Disease After a Single Injection of Mesoblast’s Cell Therapy

MELBOURNE, Australia and NEW YORK, March 15, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced 36-month results from the randomized, placebo-controlled 100-patient...
March 07, 2017 06:00 ET | Source: Mesoblast Limited

FDA Grants Fast Track Designation for Mesoblast’s Cell Therapy in Children With Acute Graft Versus Host Disease

NEW YORK and MELBOURNE, Australia, March 07, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the United States Food and Drug Administration (FDA) has...
February 26, 2017 17:07 ET | Source: Mesoblast Limited

Mesoblast Presents Corporate Update and Financial Results for the Half Year Period Ended December 31, 2016

MELBOURNE, Australia and NEW YORK, Feb. 26, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today provided the market with a strategic update, financial results for the...
February 24, 2017 16:40 ET | Source: Mesoblast Limited

Mesoblast to Host Second Quarter and First Half Financial Results Conference Call and Webcast

NEW YORK and MELBOURNE, Australia, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the second quarter/half year ended...
February 15, 2017 16:54 ET | Source: Mesoblast Limited

Durable Responses and Sustained Low Disease Activity Over Nine Months After a Single Dose of Mesoblast Cell Therapy in Rheumatoid Arthritis Patients Resistant to Anti-TNF Agents

Key points: A single intravenous infusion of Mesoblast's allogeneic "off-the-shelf" Mesenchymal Precursor Cells (MPCs) resulted in durable responses through nine months (39 weeks) in a 48-patient...
February 13, 2017 06:00 ET | Source: Mesoblast Limited

Published Study Results Show That Mesoblast Cells Administered Intravenously Significantly Ameliorate Joint Disease in Model of Early Rheumatoid Arthritis

Study provides translational and mechanistic support for Phase 2 trial results of Mesoblast’s cell therapy in patients with biologic refractory rheumatoid arthritis MELBOURNE, Australia and NEW YORK,...
January 31, 2017 06:00 ET | Source: Mesoblast Limited

Mesoblast Director Recognized by Peers for Cardiovascular Leadership

NEW YORK and MELBOURNE, Australia, Jan. 31, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that its non-executive Director, Dr Eric A. Rose, was awarded the 2017...
January 11, 2017 06:00 ET | Source: Mesoblast Limited

Mesoblast to Present at 35th Annual J.P. Morgan Healthcare Conference

MELBOURNE, Australia and NEW YORK, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO) (ASX:MSB) will host a live audio webcast at the 35th Annual J.P. Morgan Healthcare Conference....
January 09, 2017 06:00 ET | Source: Mesoblast Limited

Mesoblast Receives A$29.6 Million Following Share Issue to Mallinckrodt

NEW YORK and MELBOURNE, Australia, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has received A$29.6 million (US$21.7 million) following...
December 22, 2016 17:22 ET | Source: Mesoblast Limited

Mesoblast and Mallinckrodt Enter Into Equity Purchase Agreement to Exclusively Negotiate Development and Commercialization of Mesoblast's Cell Therapy Products for Chronic Low Back Pain and Acute Graft Versus Host Disease

NEW YORK and MELBOURNE, Australia, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has entered into an equity purchase agreement with Mallinckrodt...